Clinical trial · Interventional
Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
A Phase I , Single Arm, Dose Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC
NCT03990077CI-TRIAL-00055482terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): drug development strategy adjustment
Summary
Brief summary (as posted)
This is a phase I, open label, dose escalation study to evaluate tolerability, safety , pharmacokinetics and efficacy in patients with KRAS mutant NSCLC by using HL-085 and Docetaxel.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nsclc | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| HL-085 | Drug | Tunlametinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- dose escalation of HL-085 plus Docetaxel
- description
- HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV). f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects.
- interventionNames
- Drug: HL-085
- Drug: Docetaxel
Primary outcomes (2)
- measure
- Number of Adverse Events (AEs)
- timeFrame
- Duration of the study, estimated to be approximately 24 months
- description
- Number of Treatment-Related Adverse Events as Assessed by CTCAE v4.03 will be counted.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. KRAS mutation NSCLC. 2. One measurable lesion as defined by RECIST 1.1 criteria for solid tumors. 3. Chemotherapy, immunotherapy or radiotherapy ≥ 4 weeks prior to starting the study treatment. 4. Surgery (except for tumor biopsy) or severe trauma ≤ 14 days prior to starting the study treatment. 5. ECOG performance status of 0-1. 6. Life expectancy ≥ 3 months. 7. Ability to take the medicine orally. 8. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Hypersensitivity to study drug ingredients or their analogues. 2. Prior therapy with MEK-inhibitor. 3. Receiving any other anti-cancer therapy at the same time . 4. Active central nervous system (CNS) lesion. 5. Bleeding symptoms at Grade 3 within 4 weeks prior to starting study treatment. 6. ECG QTcB≥480msec in screening, or history of congenital long QT syndrome； 7. Uncontrolled concomitant diseases or infectious diseases. 8. Retinal diseases (Retinal Vein Occlusion (RVO) or Retinal pigment epithelial detachment (RPED) , et al.). 9. History of HIV,HCV,HBV infection. 10. Interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis will be excluded. 11. Serum HCG test is positive. 12. Other conditions that increase the risk of study and influence the result.
References
Publications (0)
Data not yet available
No reference posted for this study.